Research Papers:

Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players

Sara Franceschi, Francesca Lessi, Paolo Aretini, Valerio Ortenzi, Cristian Scatena, Michele Menicagli, Marco La Ferla, Prospero Civita, Katia Zavaglia, Claudia Scopelliti, Alessandro Apollo, Francesco Giovanni Carbone, Riccardo Vannozzi, Generoso Bevilacqua, Francesco Pasqualetti, Antonio Giuseppe Naccarato and Chiara Maria Mazzanti _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:24014-24027. https://doi.org/10.18632/oncotarget.25265

Metrics: PDF 1662 views  |   HTML 2435 views  |   ?  


Sara Franceschi1, Francesca Lessi1, Paolo Aretini1, Valerio Ortenzi2, Cristian Scatena2, Michele Menicagli1, Marco La Ferla1, Prospero Civita1, Katia Zavaglia3, Claudia Scopelliti1, Alessandro Apollo4, Francesco Giovanni Carbone2, Riccardo Vannozzi5, Generoso Bevilacqua6, Francesco Pasqualetti7, Antonio Giuseppe Naccarato2 and Chiara Maria Mazzanti1

1Fondazione Pisana per la Scienza, Onlus, Pisa, Italy

2Department of Translational Research and New Technologies in Medicine, University Hospital of Pisa, Pisa, Italy

3SOD Molecular Genetics, University Hospital of Pisa, Pisa, Italy

4Tumor Cell Biology Unit, Istituto Tumori Toscana, Florence, Italy

5Neurosurgery Department, University Hospital of Pisa, Pisa, Italy

6Pathological Anatomy Section, San Rossore Clinic, Pisa, Italy

7Radiotherapy Department, University Hospital of Pisa, Pisa, Italy

Correspondence to:

Chiara Maria Mazzanti, email: [email protected]

Keywords: glioblastoma; next generation sequencing (NGS); recurrence free survival (RFS); onco-drivers; tumor suppressors

Received: November 17, 2017     Accepted: April 02, 2018     Published: May 08, 2018


Glioblastoma is a devastating disease that despite all the information gathered so far, its optimal management remains elusive due to the absence of validated targets from clinical studies. A better clarification of the molecular mechanisms is needed. In this study, having access to IDH1 wild-type glioblastoma of patients with exceptionally long recurrence free survival (RFS), we decided to compare their mutational and gene expression profile to groups of IDH1 wild-type glioblastoma of patients with shorter RFS, by using NGS technology. The exome analysis revealed that Long-RFS tumors have a lower mutational rate compared to the other groups. A total of 158 genes were found differentially expressed among the groups, 112 of which distinguished the two RFS extreme groups. Overall, the exome data suggests that shorter RFS tumors could be, chronologically, in a more advanced state in the muli-step tumor process of sequential accumulation of mutations. New players in this kind of cancer emerge from the analysis, confirmed at the RNA/DNA level, identifying, therefore, possible oncodrivers or tumor suppressor genes.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25265